NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for
the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
Phase:
Phase 2
Details
Lead Sponsor:
Kaiser Permanente
Collaborators:
Beth Israel Deaconess Medical Center Cedars-Sinai Medical Center National Heart, Lung, and Blood Institute (NHLBI)